- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Lupin Launches Topiramate Extended-Release Capsules in the United States
The new generic drug is bioequivalent to Trokendi XR and indicated for seizures and migraine prevention.
Published on Feb. 5, 2026
Got story updates? Submit your updates here. ›
Lupin Limited, a global pharmaceutical company, has announced the launch of Topiramate Extended-Release Capsules in the United States. The new generic drug is bioequivalent to the reference listed drug Trokendi XR and is indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome, as well as for the preventive treatment of migraine.
Why it matters
The launch of Lupin's Topiramate Extended-Release Capsules provides patients and healthcare providers with a new, more affordable generic treatment option for various seizure disorders and migraine prevention. This is expected to increase access to these important medications.
The details
Topiramate Extended-Release Capsules are available in 25 mg, 50 mg, 100 mg, and 200 mg strengths. The product has an estimated annual sales of $164 million in the U.S. market. Lupin is a global pharmaceutical leader with a strong presence in India and the U.S. across multiple therapy areas, including central nervous system conditions.
- Lupin announced the launch of Topiramate Extended-Release Capsules on February 4, 2026.
- The product received approval from the U.S. FDA for Lupin's Abbreviated New Drug Application (ANDA).
The players
Lupin Limited
A global pharmaceutical company headquartered in Mumbai, India, that specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Trokendi XR
The reference listed drug for Topiramate Extended-Release Capsules, manufactured by Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.
A pharmaceutical company that manufactures the reference listed drug Trokendi XR, which is bioequivalent to Lupin's Topiramate Extended-Release Capsules.
The takeaway
The launch of Lupin's Topiramate Extended-Release Capsules provides patients and healthcare providers with a new, more affordable generic treatment option for various seizure disorders and migraine prevention, which is expected to increase access to these important medications.
